Gordon MS - Search Results

1

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Gordon MS, et al. J Clin Oncol. 2001 Feb 1;19(3):843-50. doi: 10.1200/JCO.2001.19.3.843. J Clin Oncol. 2001. PMID: 11157038 Clinical Trial.

2

In vivo effects of recombinant human stem cell factor treatment. A morphologic and immunohistochemical study of bone marrow biopsies.

Orazi A, Gordon MS, John K, Sledge G Jr, Neiman RS, Hoffman R. Orazi A, et al. Among authors: gordon ms. Am J Clin Pathol. 1995 Feb;103(2):177-84. doi: 10.1093/ajcp/103.2.177. Am J Clin Pathol. 1995. PMID: 7531939 Clinical Trial.

3

A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.

Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. Gordon MS, et al. Blood. 1995 Jun 1;85(11):3066-76. Blood. 1995. PMID: 7538815 Free article. Clinical Trial.

4

A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.

Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, Hoffman R, Beach KJ, Kuca B, Kaye J, Sledge GW Jr. Gordon MS, et al. Blood. 1996 May 1;87(9):3615-24. Blood. 1996. PMID: 8611685 Free article. Clinical Trial.

5

Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy.

Gordon MS. Gordon MS. Cancer Chemother Pharmacol. 1996;38 Suppl:S96-8. doi: 10.1007/s002800051047. Cancer Chemother Pharmacol. 1996. PMID: 8765426 Review.

6

A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma.

Gordon MS, Battiato LA, Gonin R, Harrison-Mann BC, Loehrer PJ Sr. Gordon MS, et al. J Immunother Emphasis Tumor Immunol. 1995 Oct;18(3):179-84. doi: 10.1097/00002371-199510000-00005. J Immunother Emphasis Tumor Immunol. 1995. PMID: 8770773 Clinical Trial.

7

Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.

Orazi A, Cooper RJ, Tong J, Gordon MS, Battiato L, Sledge GW Jr, Kaye JA, Kahsai M, Hoffman R. Orazi A, et al. Among authors: gordon ms. Exp Hematol. 1996 Sep;24(11):1289-97. Exp Hematol. 1996. PMID: 8862439 Clinical Trial.

8

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J. Dutcher JP, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Cancer J Sci Am. 1997. PMID: 9457399 Review.

9

Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.

Broxmeyer HE, Orazi A, Hague NL, Sledge GW Jr, Rasmussen H, Gordon MS. Broxmeyer HE, et al. Among authors: gordon ms. Blood Cells Mol Dis. 1998 Mar;24(1):14-30. doi: 10.1006/bcmd.1998.0167. Blood Cells Mol Dis. 1998. PMID: 9516378 Clinical Trial.

10

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Atkins MB, et al. Clin Cancer Res. 1997 Mar;3(3):409-17. Clin Cancer Res. 1997. PMID: 9815699 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

585 results

Search Page

Filters